Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01JKK45VCWW0JQKAPWWA0GJ6E5> ?p ?o. }
Showing items 1 to 37 of
37
with 100 items per page.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 classification U.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 date "2025".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 language "eng".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 type journalArticle.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 hasPart 01JKK48DY68B4NAVPVP7RJ609H.pdf.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 doi "10.1200/JCO.23.02470".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 issn "0732-183X".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 issn "1527-7755".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 issue "3".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 volume "43".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 abstract "PURPOSEPatients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) have a poor prognosis. The phase I/II NP30179 study (ClinicalTrials.gov identifier: NCT03075696) evaluated glofitamab monotherapy in patients with R/R B-cell lymphomas, with obinutuzumab pretreatment (Gpt) to mitigate the risk of cytokine release syndrome (CRS) with glofitamab. We present data for patients with R/R MCL.METHODSEligible patients with R/R MCL (at least one previous therapy) received Gpt (1,000 or 2,000 mg) 7 days before the first glofitamab dose (single dose or split over 2 days if required). Glofitamab step-up dosing was administered once a day on days 8 (2.5 mg) and 15 (10 mg) of cycle 1, with a target dose of 16 or 30 mg once every 3 weeks from cycle 2 day 1 onward, for 12 cycles. Efficacy end points included investigator-assessed complete response (CR) rate, overall response rate (ORR), and duration of CR.RESULTSOf 61 enrolled patients, 60 were evaluable for safety and efficacy. Patients had received a median of two previous therapies (range, 1-5). CR rate and ORR were 78.3% (95% CI, 65.8 to 87.9) and 85.0% (95% CI, 73.4 to 92.9), respectively. In patients who had received previous treatment with a Bruton tyrosine kinase inhibitor (n = 31), CR rate was 71.0% (95% CI, 52.0 to 85.8) and ORR was 74.2% (95% CI, 55.4 to 88.1). CRS after glofitamab administration occurred in 70.0% of patients, with a lower incidence in the 2,000 mg (63.6% [grade >= 2, 22.7%]) versus 1,000 mg (87.5%; grade >= 2, 62.5%) Gpt cohort. Four adverse events led to glofitamab withdrawal (all infections).CONCLUSIONFixed-duration glofitamab induced high CR rates in heavily pretreated patients with R/R MCL; the safety profile was manageable with appropriate support.".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author F42CD592-F0ED-11E1-A9DE-61C894A0A6B4.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:0614f509-c2e4-46ad-a1b6-daf2111fd1f8.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:2100b9ab-98e9-44c3-9304-b0359074e355.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:44c0067a-a78b-4268-a627-a637b97f9994.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:4e675b13-5d72-4670-83cd-db1dfe474e18.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:541174f8-2a62-4444-abdc-a46eba2069b0.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:68319fa3-c0f4-43ea-9bb7-b4e6a6e3c43c.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:6ef92118-aacf-40d4-91de-a9c00ddf466b.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:6fea325c-9e19-4e63-8e43-c19674ff5e77.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:700eaf94-6ccd-41fe-812a-e820c48cc7af.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:78e5b5b7-6364-4414-a227-e4b9b79e51ef.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:7fe1cd56-05b9-4d9f-bef3-bbba9112b954.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:801e075b-4839-4b86-a603-a87b7a2d32be.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:80680cfd-9a79-49ed-b5e5-4d2143ed06df.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:a2c9b7df-3967-4c74-9f9a-8733e84497d3.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:a43240df-eba4-4a18-9fe6-840b419294f5.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:bfdac2e2-6b88-4f23-8040-59ebe2503d8f.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 author urn:uuid:c9249922-cc0a-47bc-93f9-a332bc0f3aa0.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 dateCreated "2025-02-08T15:52:13Z".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 dateModified "2025-02-08T15:55:07Z".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 name "Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study".
- 01JKK45VCWW0JQKAPWWA0GJ6E5 pagination urn:uuid:434cb782-6226-45fb-abfa-b73ffeb3c36e.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 publisher urn:uuid:a5afd212-9bb0-4936-b9db-29d654caa7b6.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 sameAs LU-01JKK45VCWW0JQKAPWWA0GJ6E5.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 sourceOrganization urn:uuid:6dbfcb34-2d4c-4018-943f-3ee64762deea.
- 01JKK45VCWW0JQKAPWWA0GJ6E5 type U.